NeOnc Reports Additional Partial Response in Phase 2a Study of Intranasal NEO100
Globe Newswire•17/11/2026•08:00 ET
0
Key Highlights
- ➤NEO100 objective response rate rose to 12.5% from 8.3% under RANO 2.0
- ➤Six-month progression-free survival reached 48.9%, exceeding the 20% historical benchmark
- ➤NEO100 median overall survival was 26.1 months from treatment start at recurrence
- ➤Disease control rate was 66.7%, with 13 patients showing stable disease
- ➤No treatment-related serious adverse events or discontinuations were reported
Expert Statements
Amir F. Heshmatpour, Executive Chairman, President and Chief Executive Officer of NeOnc
“We are encouraged by the additional partial response in this update. We remain focused on advancing the development of NEO100 for patients with recurrent high-grade glioma.”
Objective response rate was 12.5% (3 of 24 patients) by RANO 2.0, compared with 8.3% (2 of 24 patients) in the August topline results
Median overall survival was 26.1 months from the start of NEO100 treatment at recurrence, as previously reported
Get started
Create a free account to read the full story.
